Company Overview
Company Type: Private Company
Website: orionbiotechnology.com
Number of Employees: -
Year Founded: 2011
Total Amount Raised (CAD mm)†: 6.04
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Orion Biotechnology Canada, Ltd. operates as a drug discovery and development company that engages in the discovery and development of novel G Protein-Coupled Receptor (GPCR) targeted therapeutics for the treatment of cancer and other diseases. Its platform generates data matrices for AI-assisted lead optimization by offering drug discovery and development solutions to target peptidergic GPCRs. The company was founded in 2011 and is based in Ottawa, Canada with additional offices in Genève, Switzerland; and Krakôw, Poland.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Groper, Mark 
President, CEO & Director
Burke, Jason G.
Chief Financial Officer
Klepatsky, Anatole 
COO & Director
Jussup, John 
General Counsel & Corporate Secretary
Korczak, Bozena 
Chief Translational Research Officer
McGowan, Ian 
Chief Medical Officer

Key Board Members
Name
Title
Hecht, Thomas O.
Chairman of the Board
Groper, Mark 
President, CEO & Director
Klepatsky, Anatole 
COO & Director
Winter, Gregory 
Chair of the Scientific Advisory Board
Firestone, Theresa S.
Director
Forcione, Jean 
Director
Harstrick, Andreas 
Member of Scientific Advisory Board
Heinis, Christian 
Member of Scientific Advisory Board
Jespers, Laurent 
Member of Scientific Advisory Board
Lenz, Heinz-Josef 
Member of Scientific Advisory Board
Lublin, Fred D.
Member of Scientific Advisory Board
Rot, Antal 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
343 Preston Street 11th floor | Ottawa, ON | K1S 1N4 | Canada
Phone: 343-291-1032   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Globivest
-
Unknown
-
-
Keiretsu Chennai & Singapore
-
Unknown
-
-
Kyto Technology and Life Science, Inc. (OTCPK:KBPH)
-
Unknown
-
-
Side Door Ventures LLC
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Orion Biotechnology Polska Sp. z o.o.
Orion Biotechnology Polska Sp. z o.o. researches and develops pharmaceuticals for the prevention of sexually transmitted infections (STIs), including HIV. The company was formerly known as K2 Biomedical Sp. z o.o. and changed its name to Orion Biotechnology Polska Sp. z o.o. in June, 2018. The company was founded in 2015 and is based in Krakow, Poland. As of June 14, 2018, K2 Biomedical Sp. z o.o. operates as a subsidiary of Orion Biotechnology Canada Ltd.

Europe
Pharmaceuticals
-
-
-
Orion Biotechnology Switzerland Sàrl
Orion Biotechnology Switzerland Sàrl was incorporated in 2018 and is based in Geneva, Switzerland. Orion Biotechnology Switzerland Sàrl operates as a subsidiary of Orion Biotechnology Canada Ltd.

Europe
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-28-2021
-
Private Placement
Target
Orion Biotechnology Canada, Ltd.


-
Jun-14-2018
Jun-14-2018
Merger/Acquisition
Buyer
K2 Biomedical Sp. z o.o. (nka:Orion Biotechnology Polska Sp. z o.o.)
Orion Biotechnology Canada, Ltd.

-
Dec-31-2017
Dec-31-2017
Private Placement
Target
Orion Biotechnology Canada, Ltd.


5.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-18-2023
Product-Related Announcements
Orion Biotechnology Canada Ltd. Completes Discovery of First-In-Class Molecule Against Undrugged GPCR Target in Four Months
May-04-2023
Company Conference Presentations
Orion Biotechnology Canada Ltd. Presents at LSX World Congress, May-04-2023 11:00 AM
Feb-23-2023
Company Conference Presentations
Orion Biotechnology Canada Ltd. Presents at 2nd GPCRs - Targeted Drug Discovery Summit 2023, Feb-23-2023 11:15 AM
Nov-15-2022
Company Conference Presentations
Orion Biotechnology Canada Ltd. Presents at 13th Annual Jefferies London Healthcare Conference 2022, Nov-15-2022
Nov-14-2022
Company Conference Presentations
Orion Biotechnology Canada Ltd. Presents at Inv€$tival Showcase LSX Leaders 2022 Conference, Nov-14-2022 11:30 AM


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 28, 2023 06:17 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25
GlobalData

Sep 20, 2023 05:04 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd
Reports
71
GlobalData

Sep 15, 2023 02:10 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
38
GlobalData

Dec 10, 2022 03:46 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
36
GlobalData

Nov 24, 2022 04:08 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25
GlobalData

Sep 21, 2022 07:49 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd
Reports
67
GlobalData

Sep 15, 2022 04:09 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
36
GlobalData

Aug 25, 2022 05:09 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25
GlobalData

Jun 15, 2022 04:03 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd
Reports
66
GlobalData

Jun 10, 2022 09:38 AM
Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
36


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
OB-002 (Future), OB-002H (Future)


Upcoming Events
Date/Time
Type
Nov-13-2023
Conferences
Nov-14-2023
Company Conference Presentations
Nov-14-2023
Company Conference Presentations
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Hecht, Thomas O.
Chairman of the Board
343-291-1032
-

Groper, Mark 
President, CEO & Director
343-291-1032
-

Klepatsky, Anatole 
COO & Director
343-291-1032
-
-
Winter, Gregory 
Chair of the Scientific Advisory Board
343-291-1032
-

Firestone, Theresa S.
Director
343-291-1032
-

Forcione, Jean 
Director
343-291-1032
-

Harstrick, Andreas 
Member of Scientific Advisory Board
343-291-1032
-

Heinis, Christian 
Member of Scientific Advisory Board
343-291-1032
-

Jespers, Laurent 
Member of Scientific Advisory Board
343-291-1032
-

Lenz, Heinz-Josef 
Member of Scientific Advisory Board
343-291-1032
-

Lublin, Fred D.
Member of Scientific Advisory Board
343-291-1032
-

Rot, Antal 
Member of Scientific Advisory Board
343-291-1032
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Groper, Mark 
President, CEO & Director
343-291-1032
-

Burke, Jason G.
Chief Financial Officer
343-291-1032
-

Klepatsky, Anatole 
COO & Director
343-291-1032
-
-
Jussup, John 
General Counsel & Corporate Secretary
343-291-1032
-

Korczak, Bozena 
Chief Translational Research Officer
343-291-1032
-

McGowan, Ian 
Chief Medical Officer
343-291-1032
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
